A biopharma developing an oral psoriasis therapy used IQVIA’s MIDAS Disease to evaluate markets across 95 countries. The tool segmented opportunities by drug class, form, and strength, tracking trends among 1.6M products and 600 diseases. Insights revealed biosimilar uptake, unmet needs, and priority launch countries. The client aligned its portfolio against existing therapies, improved affordability strategies, and planned rollouts in regions with the highest unmet demand. MIDAS enabled detailed competitive analysis and resource allocation, helping maximize impact in the psoriasis landscape.

Join for free to read